Nabriva Therapeutics PLC (FRA:NTY)

€ 0.665 0.065 (10.83%) Market Cap: 1.90 Mil Enterprise Value: 753,000.00 PE Ratio: 0 PB Ratio: 0 GF Score: 27/100

Q3 2022 Nabriva Therapeutics PLC Earnings Call Transcript
Nov 10, 2022

€2.2 (-3.51%)

Earnings
Q2 2022 Nabriva Therapeutics PLC Earnings Call Transcript
Aug 03, 2022

€4.53 (+11.73%)

Earnings
Q1 2022 Nabriva Therapeutics PLC Earnings Call Transcript
May 05, 2022

€7.05 (+2.92%)

Earnings
Q4 2021 Nabriva Therapeutics PLC Earnings Call Transcript
Mar 29, 2022

€10.5 (-1.87%)

Earnings
Q3 2021 Nabriva Therapeutics PLC Earnings Call Transcript
Nov 09, 2021

€27.5

Earnings
Q2 2021 Nabriva Therapeutics PLC Earnings Call Transcript
Aug 05, 2021

€25.25 (-1.94%)

Earnings
Q1 2021 Nabriva Therapeutics PLC Earnings Call Transcript
May 06, 2021

€32.5 (-5.11%)

Earnings
Q4 2020 Nabriva Therapeutics PLC Earnings Call Transcript
Mar 11, 2021

€36.5 (-1.35%)

Earnings
Q3 2020 Nabriva Therapeutics PLC Earnings Call Transcript
Nov 05, 2020

€100 (+0.03%)

Earnings
Q2 2020 Nabriva Therapeutics PLC Earnings Call Transcript
Aug 06, 2020

€168 (+1.51%)

Earnings
Nabriva Therapeutics PLC at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 13, 2020
Q1 2020 Nabriva Therapeutics PLC Earnings Call Transcript
May 11, 2020

€151.25 (+17.48%)

Earnings
Q4 2019 Nabriva Therapeutics PLC Earnings Call Transcript
Mar 12, 2020

€237.5 (-12.04%)

Earnings
Q3 2019 Nabriva Therapeutics PLC Earnings Call Transcript
Nov 12, 2019

€445

Earnings
Nabriva Therapeutics PLC at Morgan Stanley Healthcare Conference Transcript
Sep 09, 2019
Nabriva Therapeutics plc - Special Call Transcript
Aug 19, 2019
Nabriva Therapeutics PLC at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019
Nabriva Therapeutics plc Complete Response Letter from FDA on NDA Conference Call Transcript
May 01, 2019

Nabriva Therapeutics PLC at Morgan Stanley Healthcare Conference Transcript

Sep 09, 2019 / 01:55PM GMT

Transcript

David Neil Lebowitz

Morgan Stanley, Research Division - VP

Good morning. Before we get going, let me just go through the disclosures. Please note that all important disclosures, including personal holdings disclosures, and Morgan Stanley disclosures, appear on the Morgan Stanley public website at www.morganstanley.com/researchdisclosures or at the registration desk. I'm one of the biotechnology analysts at Morgan Stanley. My name is David Lebowitz, and I am happy to have on the stage with me from Nabriva, CEO Ted Schroeder. Nabriva is a developer of first-in-class antibiotics. And certainly, the company has undergone some transition over the last year with the merger. Could you tell us a little bit about the company and its history?

Theodore R. Schroeder

Nabriva Therapeutics plc - CEO & Director

Sure. So Nabriva originally started as a research organization based in Vienna, Austria where lefamulin was discovered. So our first-in-class IV and oral antibiotics for

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.